Highlights on endoglin (CD105): From basic findings towards clinical applications in human cancer

被引：135
作者：
Fonsatti E. [1 ]
Maio M. [1 ,2 ]
机构：
[1] Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico
[2] Div. of Med. Oncology/Immunotherapy, Department of Oncology, University Hospital of Siena
来源：
Journal of Translational Medicine | / 2卷 / 1期
关键词：
CD105; Human Umbilical Vein Endothelial Cell; Hereditary Hemorrhagic Telangiectasia; CD105 Promoter; Vascular Target;
D O I：
10.1186/1479-5876-2-18
中图分类号：
学科分类号：
摘要：
Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting (s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed. © 2004 Fonsatti and Maio; licensee BioMed Central Ltd.
引用
收藏
页数：7
相关论文
共 85 条
[61]  
Velasco B., Ramirez J.R., Relloso M., Li C., Kumar S., Lopez-Bote J.P., Perez-Barriocanal F., Lopez-Novoa J.M., Cowan P.J., d'Apice A.J., Bernabeu C., Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters, Gene Ther., 8, pp. 897-904, (2001)
[62]  
Cowan P.J., Shinkel T.A., Fisicaro N., Godwin J.W., Bernabeu C., Almendro N., Rius C., Lonie A.J., Nottle M.B., Wigley P.L., Paizis K., Pearse M.J., d'Apice A.J., Targeting gene expression to endothelium in transgenic animals: A comparison of the human ICAM-2, PECAM-1 and endoglin promoters, Xenotransplantation, 10, pp. 223-231, (2003)
[63]  
Korn T., Muller R., Kontermann R.E., Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes, J. Immunother., 27, pp. 99-106, (2004)
[64]  
Savontaus M.J., Sauter B.V., Huang T.G., Woo S.L., Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells, Gene Ther., 9, pp. 972-979, (2002)
[65]  
Bredow S., Lewin M., Hofmann B., Marecos E., Weissleder R., Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin, Eur. J. Cancer, 36, pp. 675-681, (2000)
[66]  
Costello B., Li C., Duff S., Butterworth D., Khan A., Perkins M., Owens S., Al-Mowallad A.F., O'Dwyer S., Kumar S., Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target, Int. J. Cancer, 109, pp. 436-441, (2004)
[67]  
Seon B.K., Matsuno F., Haruta Y., Kondo M., Barcos M., Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin, Clin. Cancer Res., 3, pp. 1031-1044, (1997)
[68]  
Matsuno F., Haruta Y., Kondo M., Tsai H., Barcos M., Seon B.K., Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies, Clin. Cancer Res., 5, pp. 371-382, (1999)
[69]  
Tabata M., Kondo M., Haruta Y., Seon B.K., Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using <sup>125</sup>I-labeled anti-endoglin monoclonal antibodies, Int. J. Cancer, 82, pp. 737-742, (1999)
[70]  
Takahashi N., Haba A., Matsuno F., Seon B.K., Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin [CD105] monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide, Cancer Res., 61, pp. 7846-7854, (2001)
123456789